Related Experiment Video
Updated: Jan 26, 2026

Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study
Published on: March 22, 2024
P-Glycoprotein Overexpression Is Associated With Cisplatin Resistance in Human Osteosarcoma
Chao He1, Zhenyu Sun1, Robert M Hoffman2,3
1Shanghai Key Laboratory of Orthopedic Implants, Department of Orthopedic Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China.
Background/Aim:
Osteosarcoma (OS) is a diagnosed primary cancer of the bone. Despite the great advances that have been made during the past decades in OS therapy, drug resistance and tumor recurrence are still major problems. It is urgent to find novel strategies to overcome drug resistance in order to prolong the survival time of OS patients.
Materials And Methods:
Cell viability was investigated by the cell count kit-8 (CCK-8) and colony formation assays. P-Glycoprotein (P-gp) expression was analyzed by RT-qPCR and western blot. A xenograft mouse model was used to identify the synergistic efficacy of a P-gp inhibitor with cisplatin. Student's t-test was used to determine statistically significant differences.
Results:
P-gp expression levels were associated with cisplatin efficacy in OS patients. OS cells with higher P-gp expression were more resistant to cisplatin. Knockdown or inhibition of P-gp sensitized OS cells to cisplatin.
Conclusion:
Down-regulating the expression of P-gp in OS maybe a promising strategy to overcome cisplatin resistance.
Insights
Targeting P-glycoprotein (P-gp) may overcome drug resistance in osteosarcoma (OS). Inhibiting P-gp in OS cells sensitized them to cisplatin, offering a potential strategy to improve patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Osteosarcoma (OS) is a primary bone cancer with significant challenges in treatment due to drug resistance and recurrence.
- Current OS therapies face limitations, necessitating novel strategies to enhance treatment efficacy and patient survival.
Purpose of the Study:
- To investigate the role of P-glycoprotein (P-gp) in mediating cisplatin resistance in osteosarcoma.
- To evaluate the potential of P-gp inhibition as a strategy to overcome drug resistance in OS.
Main Methods:
- Assessed cell viability using CCK-8 and colony formation assays.
- Analyzed P-gp expression via RT-qPCR and western blot.
- Utilized a xenograft mouse model to test the synergistic effect of a P-gp inhibitor with cisplatin.
Main Results:
- P-gp expression levels correlated with cisplatin resistance in OS patients.
- Osteosarcoma cells with high P-gp expression exhibited increased resistance to cisplatin.
- Knockdown or inhibition of P-gp significantly sensitized OS cells to cisplatin treatment.
Conclusions:
- Down-regulating P-gp expression presents a promising therapeutic strategy for overcoming cisplatin resistance in osteosarcoma.
- Targeting P-gp may improve the efficacy of chemotherapy in OS patients.
Related Concept Videos
Matrix Proteoglycans and Glycoproteins
Resistivity
Resistance
Resistance and Conductance
Various factors impact the resistance of a conductor. Spiraling in stranded conductors increases their...
Equivalent Resistance
Vascular Resistance
The primary determinants of vascular resistance are vessel diameter, blood viscosity, and vessel length. Among these, vessel diameter plays the most significant role due to the fourth power relationship described by...

